NASDAQ$ZURA

Zura Bio Limited · Q4 2025 earnings

Q4 2025 earnings · · Before market open · Investor relations

Briefing

Zura Bio reported Q4 2025, a net loss of $18M.

For Q4 2025, Zura Bio reported a net loss of $18M. Management discussed operating trends, liquidity, and priorities as disclosed in the quarterly filing.

  • Net loss $18M.
  • Zura Bio updated strategic and capital priorities in the filing.
  • Zura Bio updated strategic and capital priorities in the filing.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$0.21

Previous: -$0.26+19.2%
Net Income

-$18M

Previous: -$22.9M+21.2%

Revenue & EPS history

Zura Bio · Revenue · Quarterly

$0

Q4 2025

Forward guidance

The filing discusses Zura Bio's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.

Tailwinds

  • Zura Bio cited execution on strategic priorities in the filing.
  • Balance sheet and liquidity support continued operations.

Headwinds

  • GAAP profitability remained under pressure in the quarter.
  • Macro, competitive, and cost pressures may affect margins.
  • Segment mix and one-time items can affect comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 10 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-1.2%

Avg return

Earnings day

-2.4%

Avg return

5 days after

-3.1%

Avg return

30 days after

36%

4 / 11 earnings

Positive

+22.8%

Q4 2023

Best reaction

-26.0%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026-3.2%-2.9%-30.5%
Q4 2025-9.5%-17.3%-13.2%
Q2 2025+6.9%+8.8%+25.8%
Q1 2025-7.6%-14.2%+0.0%
Q4 2024+4.0%+5.3%-33.0%
Q1 2024-0.6%+9.6%-14.9%
Q4 2023+22.8%+26.3%+90.1%
Q3 2023+2.8%-1.2%-4.2%
Q2 2023-0.6%-1.2%+1.8%
Q1 2023-26.0%-28.5%-3.0%
Q4 2022-1.8%-11.4%-52.5%
Q3 2022
Q2 2022
Q1 2022

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro